Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 May;65(3):300–319. doi: 10.1016/S0011-393X(04)80117-6

Postmarketing surveillance study of benazepril in chinese patients with hypertension: An open-label, experimental, epidemiologic study

Jun Lu 1, Liming Lee 1,2,*, Weihua Cao 1, Siyan Zhan 1, Guoying Zhu 3, Liqiang Dai 3, Yonghua Hu 1
PMCID: PMC3964560  PMID: 24672086

Abstract

Background

Benazepril hydrochloride is an angiotensin-converting enzyme inhibitor. Previous clinical trials show that antihypertensive treatment with benazepril provides effective blood pressure (BP) control and is generally well tolerated by patients with hypertension. However, the long-term antihypertensive effects and tolerability of benazepril remain to be established in Chinese patients with hypertension.

Objective

The aim of this study was to investigate the long-term efficacy and tolerability of benazepril in Chinese patients with essential hypertension.

Methods

This 36-month, community-based, open-label, postmarketing surveillance study was conducted in the Nanshi District (Shanghai, China). Chinese patients with essential hypertension were to receive 1 or more benazepril tablets PO QD in the morning for 36 months. Data for BP and pulse pressure (PP) were collected at baseline (month 0) and throughout the surveillance period. The rate of patients achieving BP targets (systolic BP [SBP]/diastolic BP [DBP], <140/<90 mm Hg) was determined, as was the rate of decrease in BP. Subanalyses by sex and age group also were conducted.

Results

A total of 1831 patients (1090 men, 741 women; mean [SD] age, 55.8 [10.1] years [range, 35–88 years]) entered the study. After the 36-month treatment period, 75.7% of patients receiving benazepril as prescribed (1289 patients) had achieved the SBP target, 87.4% achieved the DBP target, and 71.5% achieved both targets. After 36 months of treatment, the mean (SD) decreases in SBP, DBP, and PP were 15.1 (0.4) mm Hg, 11.0 (0.3) mm Hg, and 4.2 (0.4) mm Hg, respectively, among compliers. In general, the rate of BP decrease slowed over time. No serious adverse drug reactions (ADRs) were detected during the 36-month follow-up period. All ADRs except cough (19.9%) occurred at a relatively low incidence rate (<3.0%). The cumulative incidence of benazepril related cough was statistically significantly higher in women than in men (23.6% vs 18.8%, respectively; P = 0.007). Of the 1831 patients studied, 1360 patients (74.3%) persisted in taking benazepril and were considered optimally compliant at 36-month follow-up.

Conclusion

In this study of Chinese patients with hypertension, benazepril was associated with prolonged, stable efficacy in lowering BP and relatively low incidence of ADRs.

Full Text

The Full Text of this article is available as a PDF (1,012.7 KB).

References

  • 1.World Health Organization (WHO) Integrated management of cardiovascular risk: Report of a WHO meeting; Geneva; July 9–12, 2002. Available at: http: //www.who.int/ cardiovascular_diseases/media/en/635.pdf. Accessed April 15, 2004. [Google Scholar]
  • 2.Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol. 2002;1:149–156. doi: 10.1016/s1474-4422(02)00070-4. [DOI] [PubMed] [Google Scholar]
  • 3.Black HR. Blood pressure control. Am J Med. 1996;101:4A505–4A555. [PubMed] [Google Scholar]
  • 4.Bakir SE, Oparil S. Antihypertensive drug therapy in the third millennium: Are there benefits beyond blood pressure? Curr Hypertens Rep. 2000;2:291–294. doi: 10.1007/s11906-000-0012-4. [DOI] [PubMed] [Google Scholar]
  • 5.Sacristán JA, Gomez JC, Montejo AL. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study. EFESO Study GroupClin Ther. 2000;22:583–599. doi: 10.1016/s0149-2918(00)80046-6. [DOI] [PubMed] [Google Scholar]
  • 6.WHO-ISH Guidelines Subcommittee 1999 World Health Organization—International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151–183. [PubMed] [Google Scholar]
  • 7.The Sixth Report of the Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413–2446. doi: 10.1001/archinte.157.21.2413. [published correction appears in Arch Intern Med. 1998; 158: 573] [DOI] [PubMed] [Google Scholar]
  • 8.
  • 9.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. [PubMed] [Google Scholar]
  • 10.Brown H, Prescott R. John Wiley & Sons; London, UK: 1999. Applied Mixed Models in Medicine. [Google Scholar]
  • 11.Karch FE, Lasagna L. Adverse drug reactions. A critical reviewJAMA. 1975;234:1236–1241. [PubMed] [Google Scholar]
  • 12.Ployhart RE, Holtz BC, Bliese PD. Longitudinal data analysis—applications of random coefficient modeling to leadership research. Leadersh Q. 2002;13:455–486. [Google Scholar]
  • 13.
  • 14.
  • 15.Raudenbush SW, Bryk AS. Applications and Data Analysis Methods. 2nd ed. Sage; Chichester, UK: 2002. Hierarchical linear models. [Google Scholar]
  • 16.Singer JD. Vol. 24. 1998. Using SAS Proc Mixed to fit multilevel models, hierarchical models, and individual growth models; pp. 323–355. (J Educ Behav Stat). Available at: http: // gseweb.harvard.edu/∼faculty/singer/sasprocmixed.pdf. Accessed April 15, 2004. [Google Scholar]
  • 17.Khattree R, Naik DN. 2nd ed. SAS Publishing; Newbury Park, Calif: 1999. Applied Multivariate Statistics with SAS Software; pp. 165–167. [Google Scholar]
  • 18.
  • 19.
  • 20.
  • 21.Johnson M. April 15, 2004. Individual growth analysis using PROC MIXED. Available at: http: // www2.sas.com/proceedings/sugi27/p253-27.pdf. Accessed. [Google Scholar]
  • 22.Psaty BM, Smith NL, Siscovick DS. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and metaanalysis. JAMA. 1997;277:739–745. [PubMed] [Google Scholar]
  • 23.Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol. 1996;77:12B–16B. doi: 10.1016/s0002-9149(97)89233-8. [DOI] [PubMed] [Google Scholar]
  • 24.Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combination vs monotherapy in hypertension: A meta-analysis evaluation. J Hum Hypertens. 1999;13:477–483. doi: 10.1038/sj.jhh.1000855. [DOI] [PubMed] [Google Scholar]
  • 25.Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens. 1990;8:393–405. doi: 10.1097/00004872-199005000-00001. [DOI] [PubMed] [Google Scholar]
  • 26.Staessen J, O'Brien E, Atkins N. The increase in blood pressure with age and body mass index is overestimated by conventional sphygmomanometry. Am J Epidemiol. 1992;136:450–459. doi: 10.1093/oxfordjournals.aje.a116518. [DOI] [PubMed] [Google Scholar]
  • 27.Franklin SS, Gustin W, 4th, Wong ND. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart StudyCirculation. 1997;96:308–315. doi: 10.1161/01.cir.96.1.308. [DOI] [PubMed] [Google Scholar]
  • 28.Douglas JG, Bakris GL, Epstein M, for the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525–541. doi: 10.1001/archinte.163.5.525. [DOI] [PubMed] [Google Scholar]
  • 29.Lip GYH, Beevers DG. A survey of the current practice of treating hypertension in primary care: The rational evaluation and choice in hypertension (REACH) study. J Drug Dev Clin Pract. 1996;8:161–169. [Google Scholar]
  • 30.Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: Is drug choice a factor in treatment adherence? Curr Hypertens Rep. 2000;2:515–524. doi: 10.1007/s11906-996-0035-6. [DOI] [PubMed] [Google Scholar]
  • 31.Dusing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy—the role of adverse effects and compliance. Blood Press. 1998;7:313–315. doi: 10.1080/080370598437187. [DOI] [PubMed] [Google Scholar]
  • 32.Conlin PR, Gerth WC, Fox J. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther. 2001;23:1999–2010. doi: 10.1016/s0149-2918(01)80152-1. [DOI] [PubMed] [Google Scholar]
  • 33.Benson S, Vance-Bryan K, Raddatz J. Time to patient discontinuation of antihypertensive drugs in difference classes. Am J Health Syst Pharm. 2000;57:51–54. doi: 10.1093/ajhp/57.1.51. [DOI] [PubMed] [Google Scholar]
  • 34.Jouglard J, Hamel J-D, Juvin P. A pharmacoepidemiologic study of trandolapril. Curr Ther Res Clin Exp. 1997;58:555–563. [Google Scholar]
  • 35.Porcellati C, Verdecchia P, Schillaci G. Long-term effects of benazepril on ambulatory blood pressure, left ventricular mass, diastolic filling and aortic flow in essential hypertension. Int J Clin Pharmacol Ther Toxicol. 1991;29:187–197. [PubMed] [Google Scholar]
  • 36.Nordrehaug JE, Omsjo IH, Vollset SE. A 3-month double-blind cross-over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure. J Intern Med. 1992;231:589–594. doi: 10.1111/j.1365-2796.1992.tb01244.x. [DOI] [PubMed] [Google Scholar]
  • 37.Chen CH, Hsu TL, Lin SJ. Short-term and long-term effects of benazepril in mild to moderate hypertensives. Zhonghua Yi Xue Za Zhi (Taipei) 1995;56:12–22. [in Chinese] [PubMed] [Google Scholar]
  • 38.Maschio G, Alberti D, Janin G, for the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939–945. doi: 10.1056/NEJM199604113341502. [DOI] [PubMed] [Google Scholar]
  • 39.Pall D, Juhasz A, Karanyi Z. Efficacy of benazepril monotherapy in moderate essential hypertension studied by automatic ambulatory blood pressure monitoring. Orv Hetil. 1996;137:1973–1978. [in Hungarian] [PubMed] [Google Scholar]
  • 40.Haziza HM, Francillon A, Mottier D. Antihypertensive action and predictive factors of efficacy of benazepril in mild-to-moderate hypertension: Clinical trial in general medical practice on 16, 987 patients. Ann Cardiol Angeiol (Paris) 1998;47:33–41. [in French] [PubMed] [Google Scholar]
  • 41.Maschio G, Alberti D, Locatelli F, for the ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group Angiotensin-converting enzyme inhibitors and kidney protection: The AIPRI trial. J Cardiovasc Pharmacol. 1999;33(Suppl 1):S16–S20. doi: 10.1097/00005344-199900001-00004. discussion. [DOI] [PubMed] [Google Scholar]; Maschio G, Alberti D, Locatelli F, for the ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group Angiotensin-converting enzyme inhibitors and kidney protection: The AIPRI trial. J Cardiovasc Pharmacol. 1999;33(Suppl 1):S41–S43. doi: 10.1097/00005344-199900001-00004. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES